Theratechnologies Inc., of Montreal, reported that for the third quarter ended Aug. 31, consolidated revenue for the three- and nine-month periods totaled $16.11 million and $46.8 million, respectively, compared to $13.52 million and $31.23 million, respectively, for the same periods last year, an increase of 19.1% and 49.9%. Both three- and nine-month increases in revenue are mostly attributable to increasing sales of Trogarzo (ibalizumab), for the treatment of multidrug-resistant HIV-1 patients, which reached $6.92 million in the third quarter of 2019 compared to $3.71 million for the same quarter last year, representing an 86.5% increase. Egrifta (tesamorelin), for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, generated sales of $9.2 million in the third quarter compared to $9.8 million for the same quarter last year.The company recorded a net loss of $1.63 million, or 2 cents per share, in the third quarter of fiscal 2019 and a net loss of $6 million, or 8 cents per share, for the nine-month period. As of Aug. 31, its cash position was $44.1 million.

No Comments